Compare Eli Lilly And Co (LLY) vs NetApp Inc. (NTAP) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

NetApp (NTAP) trades at $161.16, down 1.66% on the day, near its pivot point of $164. The stock exhibits a bullish technical trend with strong moving average signals. Fundamentally, the company shows robust profitability with a net income margin of 18.43% and has beaten earnings estimates for three consecutive quarters. Recent strategic moves include the acquisition of DataPelago to bolster AI data infrastructure capabilities, signaling growth focus.

The outlook for NTAP is positive, driven by AI-driven demand and consistent earnings outperformance, though risks include competitive pressures and reliance on enterprise spending. Analyst consensus leans bullish with a price target of $167.45, offering modest upside from current levels.